COMMUNIQUÉS West-GlobeNewswire

BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
12/11/2025
MELVILLE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
12/11/2025
Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M Announced strategic [...]
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
12/11/2025
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, [...]
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
12/11/2025
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
12/11/2025
Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive interim Phase 2 data [...]
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
12/11/2025
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to [...]
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
12/11/2025
- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with [...]
Kura Oncology to Participate in Upcoming Investor Conference
12/11/2025
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
12/11/2025
Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relations Advanced multiple [...]
GE HealthCare and RadNet’s DeepHealth Division Sign Letter of Intent to Advance Innovation and Adoption of AI-Powered Imaging Across Multiple Modalities and Remote Scanning
12/11/2025
Collaboration aims to expand existing U.S. relationship combining GE HealthCare’s mammography systems with DeepHealth’s Breast Suite to include a worldwide distribution arrangement Intends to integrate GE HealthCare’s [...]
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
12/11/2025
ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA [...]
MaxCyte Announces Planned CFO Transition in 2026
12/11/2025
Company initiates search for successor ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance [...]
LogicMark, Inc. Announces Third Quarter 2025 Results
12/11/2025
Revenue increases 8% Year-Over-Year and 9% Year-To-Date LOUISVILLE, Ky., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc.  (OTC: LGMKD) (the Company), a provider of personal safety and emergency response systems (PERS [...]
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
12/11/2025
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated [...]
LeMaitre to Participate in Upcoming Investor Conferences
12/11/2025
BURLINGTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences. Jefferies London Healthcare Conference [...]
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
12/11/2025
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to James Rawls, the new Senior Vice President of Regulatory [...]
Inventiva annonce le lancement d'une offre au public
12/11/2025
Daix (France), New York City (New York, États-Unis ), 12 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Inventiva announces launch of public offering
12/11/2025
Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the [...]
Solana Company to Release Third Quarter Operating Results on November 18, 2025
12/11/2025
NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to [...]

Pages